- Home
- CYTH vs FGEN Comparison
CYTH vs FGEN Comparison
Compare CYTH & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYTH
- FGEN
- Stock Information
- Founded
- CYTH 1990
- FGEN 1993
- Country
- CYTH United States
- FGEN United States
- Employees
- CYTH N/A
- FGEN N/A
- Industry
- CYTH Biotechnology: Pharmaceutical Preparations
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- CYTH Health Care
- FGEN Health Care
- Exchange
- CYTH Nasdaq
- FGEN Nasdaq
- Market Cap
- CYTH 31.9M
- FGEN 34.5M
- IPO Year
- CYTH N/A
- FGEN 2014
- Fundamental
- Price
- CYTH $0.91
- FGEN $0.71
- Analyst Decision
- CYTH Buy
- FGEN Strong Buy
- Analyst Count
- CYTH 3
- FGEN 1
- Target Price
- CYTH $0.95
- FGEN $10.00
- AVG Volume (30 Days)
- CYTH 4.5M
- FGEN 7.1M
- Earning Date
- CYTH 03-17-2025
- FGEN 03-04-2025
- Dividend Yield
- CYTH N/A
- FGEN N/A
- EPS Growth
- CYTH N/A
- FGEN N/A
- EPS
- CYTH N/A
- FGEN N/A
- Revenue
- CYTH $870,725.00
- FGEN $180,015,000.00
- Revenue This Year
- CYTH N/A
- FGEN $21.91
- Revenue Next Year
- CYTH $24.49
- FGEN N/A
- P/E Ratio
- CYTH N/A
- FGEN N/A
- Revenue Growth
- CYTH N/A
- FGEN 16.15
- 52 Week Low
- CYTH $0.55
- FGEN $0.18
- 52 Week High
- CYTH $1.79
- FGEN $2.80
- Technical
- Relative Strength Index (RSI)
- CYTH 53.59
- FGEN 65.95
- Support Level
- CYTH $0.85
- FGEN $0.54
- Resistance Level
- CYTH $1.45
- FGEN $0.88
- Average True Range (ATR)
- CYTH 0.13
- FGEN 0.07
- MACD
- CYTH -0.00
- FGEN 0.02
- Stochastic Oscillator
- CYTH 22.83
- FGEN 59.79
About CYTH Cyclo Therapeutics Inc.
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The Company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.